These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34818411)

  • 21. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.
    Al Jalali V; Scherzer S; Zeitlinger M
    Clin Microbiol Infect; 2021 Oct; 27(10):1529-1530. PubMed ID: 34192576
    [No Abstract]   [Full Text] [Related]  

  • 22. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
    Bertrand D; Lemée V; Laurent C; Lemoine M; Hanoy M; Le Roy F; Nezam D; Pruteanu D; Lebourg L; Grange S; Plantier JC; Boyer O; Guerrot D; Candon S
    Am J Transplant; 2022 May; 22(5):1498-1500. PubMed ID: 35007383
    [No Abstract]   [Full Text] [Related]  

  • 23. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.
    Attolico I; Tarantini F; Carluccio P; Schifone CP; Delia M; Gagliardi VP; Perrone T; Gaudio F; Longo C; Giordano A; Sgherza N; Curci P; Rizzi R; Ricco A; Russo Rossi A; Albano F; Larocca AMV; Vimercati L; Tafuri S; Musto P
    Br J Haematol; 2022 Feb; 196(4):928-931. PubMed ID: 34664267
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence.
    Daungsupawong H; Wiwanitkit V
    Semergen; 2024; 50(4):102132. PubMed ID: 38295632
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
    Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
    BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
    Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
    Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
    Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
    J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.
    Mulhern JG; Fadia A; Patel R; Ficociello LH; Willetts J; Dahne-Steuber IA; Pollan MC; Mullon C; DeLisi J; Johnson C; Mysayphonh C; Kossmann RJ; Anger MS; Hymes JL
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1720-1722. PubMed ID: 34312162
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
    Crickx E; Moulis G; Ebbo M; Terriou L; Briantais A; Languille L; Limal N; Guillet S; Michel M; Mahevas M; Godeau B
    Br J Haematol; 2021 Dec; 195(5):703-705. PubMed ID: 34467525
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.
    Grunau B; Goldfarb DM; Asamoah-Boaheng M; Golding L; Kirkham TL; Demers PA; Lavoie PM
    JAMA; 2022 Jan; 327(3):279-281. PubMed ID: 34860253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
    Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
    Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
    Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
    Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Melmed GY; Botwin GJ; Sobhani K; Li D; Prostko J; Figueiredo J; Cheng S; Braun J; McGovern DPB
    Ann Intern Med; 2021 Dec; 174(12):1768-1770. PubMed ID: 34633830
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
    Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
    [No Abstract]   [Full Text] [Related]  

  • 39. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
    Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
    Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
    Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
    JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.